Table of Contents

1 Report Overview

• 1.1 Research Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Afatinib Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 ≥98%
  • 1.3.3 ＜98%
• 1.4 Market Segment by Application
  • 1.4.1 Global Afatinib Market Share by Application (2019-2025)
  • 1.4.2 Non-Small Cell Lung Cancer
  • 1.4.3 Application II
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Production and Capacity Analysis
  • 2.1.1 Global Afatinib Production Value 2014-2025
  • 2.1.2 Global Afatinib Production 2014-2025
  • 2.1.3 Global Afatinib Capacity 2014-2025
  • 2.1.4 Global Afatinib Marketing Pricing and Trends
• 2.2 Key Producers Growth Rate (CAGR) 2019-2025
  • 2.2.1 Global Afatinib Market Size CAGR of Key Regions
  • 2.2.2 Global Afatinib Market Share of Key Regions
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Capacity and Production by Manufacturers
  • 3.1.1 Global Afatinib Capacity by Manufacturers
  • 3.1.2 Global Afatinib Production by Manufacturers
• 3.2 Revenue by Manufacturers
  • 3.2.1 Afatinib Revenue by Manufacturers (2014-2019)
  • 3.2.2 Afatinib Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Afatinib Market Concentration Ratio (CR5 and HHI)
• 3.3 Afatinib Price by Manufacturers
• 3.4 Key Manufacturers Afatinib Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Afatinib Market
• 3.6 Key Manufacturers Afatinib Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Production and Production Value for Each Type
  • 4.1.1 ≥98% Production and Production Value (2014-2019)
  • 4.1.2 ＜98% Production and Production Value (2014-2019)
• 4.2 Global Afatinib Production Market Share by Type
• 4.3 Global Afatinib Production Value Market Share by Type
• 4.4 Afatinib Ex-factory Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Afatinib Consumption by Application

6 Production by Regions

• 6.1 Global Afatinib Production (History Data) by Regions 2014-2019
• 6.2 Global Afatinib Production Value (History Data) by Regions
• 6.3 United States
  • 6.3.1 United States Afatinib Production Growth Rate 2014-2019
  • 6.3.2 United States Afatinib Production Value Growth Rate 2014-2019
  • 6.3.3 Key Players in United States
  • 6.3.4 United States Afatinib Import & Export
• 6.4 European Union
  • 6.4.1 European Union Afatinib Production Growth Rate 2014-2019
  • 6.4.2 European Union Afatinib Production Value Growth Rate 2014-2019
  • 6.4.3 Key Players in European Union
  • 6.4.4 European Union Afatinib Import & Export
• 6.5 China
  • 6.5.1 China Afatinib Production Growth Rate 2014-2019
  • 6.5.2 China Afatinib Production Value Growth Rate 2014-2019
  • 6.5.3 Key Players in China
  • 6.5.4 China Afatinib Import & Export
• 6.6 Rest of World
  • 6.6.1 Japan
  • 6.6.2 Korea
  • 6.6.3 India
  • 6.6.4 Southeast Asia

7 Afatinib Consumption by Regions

• 7.1 Global Afatinib Consumption (History Data) by Regions
• 7.2 United States
  • 7.2.1 United States Afatinib Consumption by Type
  • 7.2.2 United States Afatinib Consumption by Application
• 7.3 European Union
  • 7.3.1 European Union Afatinib Consumption by Type
  • 7.3.2 European Union Afatinib Consumption by Application
• 7.4 China
  • 7.4.1 China Afatinib Consumption by Type
  • 7.4.2 China Afatinib Consumption by Application
• 7.5 Rest of World
  • 7.5.1 Rest of World Afatinib Consumption by Type
  • 7.5.2 Rest of World Afatinib Consumption by Application
  • 7.5.1 Japan
  • 7.5.2 Korea
  • 7.5.3 India
  • 7.5.4 Southeast Asia

8 Company Profiles

• 8.1 Boehringer Ingelheim
  • 8.1.1 Boehringer Ingelheim Company Details
  • 8.1.2 Company Description and Business Overview
  • 8.1.3 Production and Revenue of Afatinib
  • 8.1.4 Afatinib Product Introduction
  • 8.1.5 Boehringer Ingelheim Recent Development
• 8.2 Teva Pharmaceutical Industries
  • 8.2.1 Teva Pharmaceutical Industries Company Details
  • 8.2.2 Company Description and Business Overview
  • 8.2.3 Production and Revenue of Afatinib
  • 8.2.4 Afatinib Product Introduction
  • 8.2.5 Teva Pharmaceutical Industries Recent Development
• 8.3 Myosynth
  • 8.3.1 Myosynth Company Details
  • 8.3.2 Company Description and Business Overview
  • 8.3.3 Production and Revenue of Afatinib
  • 8.3.4 Afatinib Product Introduction
  • 8.3.5 Myosynth Recent Development
• 8.4 Reva Pharma
  • 8.4.1 Reva Pharma Company Details
  • 8.4.2 Company Description and Business Overview
  • 8.4.3 Production and Revenue of Afatinib
  • 8.4.4 Afatinib Product Introduction
  • 8.4.5 Reva Pharma Recent Development
• 8.5 Tianjin Scipharmacn
  • 8.5.1 Tianjin Scipharmacn Company Details
  • 8.5.2 Company Description and Business Overview
  • 8.5.3 Production and Revenue of Afatinib
  • 8.5.4 Afatinib Product Introduction
  • 8.5.5 Tianjin Scipharmacn Recent Development
• 8.6 Hubei Purple Sakura Chemical
  • 8.6.1 Hubei Purple Sakura Chemical Company Details
  • 8.6.2 Company Description and Business Overview
  • 8.6.3 Production and Revenue of Afatinib
  • 8.6.4 Afatinib Product Introduction
  • 8.6.5 Hubei Purple Sakura Chemical Recent Development

9 Market Forecast

• 9.1 Global Market Size Forecast
  • 9.1.1 Global Afatinib Capacity, Production Forecast 2019-2025
  • 9.1.2 Global Afatinib Production Value Forecast 2019-2025
• 9.2 Market Forecast by Regions
  • 9.2.1 Global Afatinib Production and Value Forecast by Regions 2019-2025
  • 9.2.2 Global Afatinib Consumption Forecast by Regions 2019-2025
• 9.3 United States
  • 9.3.1 Production and Value Forecast in United States
  • 9.3.2 Consumption Forecast in United States
• 9.4 European Union
  • 9.4.1 Production and Value Forecast in European Union
  • 9.4.2 Consumption Forecast in European Union
• 9.5 China
  • 9.5.1 Production and Value Forecast in China
  • 9.5.2 Consumption Forecast in China
• 9.6 Rest of World
  • 9.6.1 Japan
  • 9.6.2 Korea
  • 9.6.3 India
  • 9.6.4 Southeast Asia
• 9.7 Forecast by Type
  • 9.7.1 Global Afatinib Production Forecast by Type
  • 9.7.2 Global Afatinib Production Value Forecast by Type
• 9.8 Consumption Forecast by Application

10 Value Chain and Sales Channels Analysis

• 10.1 Value Chain Analysis
• 10.2 Sales Channels Analysis
  • 10.2.1 Afatinib Sales Channels
  • 10.2.2 Afatinib Distributors
• 10.3 Afatinib Customers

11 Opportunities & Challenges, Threat and Affecting Factors

• 11.1 Market Opportunities
• 11.2 Market Challenges
• 11.3 Porter's Five Forces Analysis

12 Key Findings

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
    • 13.1.1.1 Research Programs/Design
    • 13.1.1.2 Market Size Estimation
    • 13.1.1.3 Market Breakdown and Data Triangulation
  • 13.1.2 Data Source
    • 13.1.2.1 Secondary Sources
    • 13.1.2.2 Primary Sources
• 13.2 Author Details

In 2019, the market size of Afatinib is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Afatinib.

This report studies the global market size of Afatinib, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Afatinib production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Boehringer Ingelheim
Teva Pharmaceutical Industries
Myosynth
Reva Pharma
Tianjin Scipharmacn
Hubei Purple Sakura Chemical
...

Market Segment by Product Type
≥98%
＜98%

Market Segment by Application
Non-Small Cell Lung Cancer
Application II

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Afatinib status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Afatinib manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Afatinib are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025